ELISA: 1/10000-1/20000. Western Blot: 1/500-1/1000. Immunohistochemistry: 1/50-1/200. Immunoprecipitation: 1/50-1/200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3), and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Neu, a 185 kDa glycoprotein, undergoes transactivation upon heterodimerizaion with other EGF receptor family members. Neu heterodimerization with ErbB-3 recruits heregulin, which induces phosphoinositide (PI) 3-kinase activation. Activation of Neu potentiates tumor cell motility and protease secretion and invasion, and also modulates cell cycle checkpoint function, DNA repair and apoptotic responses. Amplification and/or overexpression of Neu occurs in 20-30 % of breast carcinomas. Measurement of increased Neu expression can be a predictor of disease prognosis. Neu may also prove to bea promising target for therapeutic agents.Synonyms: HER-2, MNL19, NEU, NEU proto-oncogene, NGL, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erbB-2, p185erbB2